Skip the MOTS-c - but do add the IPA with Tesa. These work together for a higher than either alone benefit (2+2=5)
MOTS-c is unrelated and has comparatively lower level of study supporting it.
The simultaneous use of Tesamorelin and Ipamorelin leverages a biochemical synergy to optimize growth hormone (GH) therapy. While direct human trials for this exact combination remain scarce, the physiological rationale is well-established across endocrinology literature (
Mayfield, 2026).
This protocol mimics the body’s natural, dual-signaling mechanism for GH release. Tesamorelin is an FDA-approved Growth Hormone-Releasing Hormone (GHRH) analogue that binds to GHRH receptors on the pituitary to kickstart a natural, pulsatile surge of GH. This specific peptide is clinically proven to dramatically decrease visceral adipose tissue and improve lean muscle mass quality (
Adrian et al., 2019). Meanwhile, Ipamorelin acts via a completely separate pathway as a selective Growth Hormone Secretagogue (GHS) and ghrelin receptor agonist (
Sinha et al., 2020).
When paired, these pathways act synergistically (
Veldhuis & Bowers, 2009). Ipamorelin dramatically amplifies the peak amplitude of the GH pulse initiated by Tesamorelin, while simultaneously neutralizing somatostatin—the inhibitory hormone that halts GH production. This dual action triggers a highly potent, sustained elevation of natural GH and downstream Insulin-like Growth Factor 1 (IGF-1). This achieves optimized body recomposition and enhanced recovery without causing the organomegaly or systemic side effects tied to synthetic, exogenous human growth hormone injections (
Sinha et al., 2020).